How do ductal carcinoma in situ (DCIS) and invasive lobular carcinoma (ILC) differ in terms of presentation, diagnosis, and management?

DCIS vs Invasive Lobular Carcinoma: Key Differences

DCIS and invasive lobular carcinoma (ILC) are fundamentally different entities—DCIS is a noninvasive precursor lesion with excellent prognosis (96-100% 10-year survival), while ILC is an invasive malignancy with distinct growth patterns, requiring different diagnostic approaches and treatment strategies.

Presentation

DCIS

• Approximately 85% detected solely by mammography as microcalcifications (pleomorphic, varying in size, clustered in linear or segmental arrangements reflecting ductal distribution) 1, 2
• Usually nonpalpable and cannot be identified grossly 1
• When clinically evident: palpable mass or bloody nipple discharge (now uncommon) 1
• Negligible risk of metastases at diagnosis 2

Invasive Lobular Carcinoma

• Subtle clinical and imaging presentation due to infiltrative growth pattern with low desmoplasia 3
• More frequently diagnosed at later stages with more lymph node involvement compared to invasive ductal carcinoma 4
• Larger tumor sizes at detection (T3/T4: 14.3% vs 3.4% for ductal) 4
• Mammographic features often subtle: architectural distortion or focal asymmetries rather than discrete masses 3
• Discohesive growth pattern makes detection challenging 5

Diagnosis

DCIS Pathology Requirements 1

Critical pathology report elements:

• Nuclear grade (most consistent classification factor)
• Presence/absence of necrosis
• Architectural pattern
• Estimated extent/size (difficult due to nonpalpable nature)
• Surgical margin status (most important aspect—specify if DCIS transected at margin and distance from nearest margin)
• Microcalcification location

Note: Estrogen/progesterone receptors, DNA ploidy, S-phase, and oncogene amplification are not necessary for DCIS 1

ILC Diagnosis

• Absence of e-cadherin staining is crucial for differentiation from ductal lesions 3
• Histologically: discohesive neoplastic cells, infiltrative growth, low desmoplasia 3
• MRI exhibits high sensitivity for ILC diagnosis and detecting synchronous lesions 3
• Ultrasound detects ~75% of ILCs missed by mammography 3
• More frequently ER-positive, lower grade (90% grade 1-2) but larger size 4

Management Differences

DCIS Treatment Algorithm 1, 6, 7

Surgical Options:

• Breast-conserving surgery (BCS) + whole-breast radiotherapy OR mastectomy (no survival difference between approaches) 1
• 2-mm margin is adequate when treated with BCS + radiotherapy 7
• Margins <2mm or positive: re-excision required

Radiation Therapy:

• Reduces ipsilateral breast recurrence by 50-70% 6
• 10-year recurrence rates: 6-23% with BCS + radiation 1
• 50% of recurrences are invasive cancers (appearing at later intervals, ~5 years) 1

Axillary Management:

• SLNB NOT routinely required 6, 7
• Consider SLNB only for: large tumors, high-grade, mastectomy planned (risk of occult invasion 20-38%) 7
• Risk of positive SLN with pure DCIS: 7-9% (mostly micrometastases) 7

Outcomes:

• 10-year cause-specific survival: 96-100% 1
• Local recurrence with mastectomy: rare 1

ILC Treatment Considerations 5

Imaging:

• MRI recommended for preoperative staging to improve accuracy 5
• Account for imaging limitations regarding margin assessment in lumpectomy 5

Surgical Approach:

• Higher mastectomy rates (57% vs 46% for ER-positive ductal) due to larger size and multifocality 4
• ALND omission trials included ILC patients—safe in appropriately selected patients 5

Systemic Therapy:

• Base neoadjuvant therapy on molecular subtype rather than histology 5
• ILC derives distinct benefit from systemic therapy compared to ductal carcinoma 8

Genetic Testing:

• Include CDH1 mutation analysis (specific to lobular pathology) 5

Outcomes:

• ER-positive ILC has worse disease-free survival and overall survival compared to ER-positive ductal carcinoma despite lower grade 4

Critical Pitfalls

DCIS

• Underestimating extent: DCIS difficult to measure grossly—requires careful pathologic correlation 1
• Positive/close margins: 29% crude recurrence rate vs 7% with negative margins 1
• Young age/family history: Controversial association with higher recurrence (some studies show ~40% vs ~10%) 1
• Comedo/high-grade DCIS: Earlier recurrence (median 3.1 years vs 6.5 years for non-comedo), but 10-year rates similar (18% vs 15%) 1

ILC

• Mammographic subtlety: Requires heightened suspicion—use ultrasound and MRI liberally 3
• Margin assessment: Infiltrative growth makes clear margins challenging 5
• Size underestimation: Mean ILC size at diagnosis has increased yearly since 1990 4
• Synchronous lesions: Higher risk—MRI essential for detection 3